What is AnaptysBio, Inc.'s R&D?

AnaptysBio, Inc. (ANAB) reported R&D of $33.99M in Q1 2026.

How has AnaptysBio, Inc.'s R&D changed year-over-year?

AnaptysBio, Inc.'s R&D decreased by 17.5% year-over-year, from $41.18M to $33.99M.

What is the long-term trend for AnaptysBio, Inc.'s R&D?

Over 4 years (2021 to 2025), AnaptysBio, Inc.'s R&D has grown at a 8.4% compound annual growth rate (CAGR), from $98.5M to $135.97M.

Costs of research activities to discover new knowledge and development activities to translate research into new or improved products, services, processes, or technologies.

AnaptysBio, Inc. ANAB R&D

R&D at other companies

Bristol-Myers SquibbBMY

$2.65B+17.4%

Eli LillyLLY

$3.51B+28.4%

AmgenAMGN

$1.72B+15.7%

Regeneron PharmaceuticalsREGN

$1.54B+16.3%

BiogenBIIB

$539M+24.2%

Dianthus TherapeuticsDNTH

$34.53M+27.9%

Segments

By segment

See full

Biopharma Company$139.61M—

Royalty Management Company-$3.64M—

Other financials

Income statement

See full

Revenue$25.6M-8.0%

Operating income-$34.6M-25.8%

Net income-$52.9M-34.5%

EPS (diluted)-$1.84-43.8%

Balance sheet

See full

Cash & equivalents$248.5M+152%

Total debt$13.6K-99.9%

Total equity$12.7M-62.5%

Total assets$329.7M-21.9%

Cash flow

See full

Operating cash flow-$25.9M-142%

CapEx$17.0K-51.4%

Free cash flow-$25.9M-142%

Valuation

See full

Market cap$1.73B+180%

Enterprise value$1.48B+176%

P/S7.4×+1.9×

Profitability

See full

Operating margin17.6%+9.6pp

Net margin-49.9%-22.6pp

FCF margin1.9%+1.0pp

Returns & leverage

See full

Return on equity-343.8%-1,012pp

Debt / equity0×-0.5×

Current ratio7.6×-0.7×

Where this comes from

Reported directly by AnaptysBio, Inc. in its filing.

Tagged under the XBRL concept us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost.

The official record: AnaptysBio, Inc.’s 10-Q, filed May 12, 2026, on SEC EDGAR. View the filing →

Ask your AI about AnaptysBio, Inc.'s r&d.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI

Claude

Questions, answered.

What is AnaptysBio, Inc.'s R&D?: AnaptysBio, Inc. (ANAB) reported R&D of $33.99M in Q1 2026.
How has AnaptysBio, Inc.'s R&D changed year-over-year?: AnaptysBio, Inc.'s R&D decreased by 17.5% year-over-year, from $41.18M to $33.99M.
What is the long-term trend for AnaptysBio, Inc.'s R&D?: Over 4 years (2021 to 2025), AnaptysBio, Inc.'s R&D has grown at a 8.4% compound annual growth rate (CAGR), from $98.5M to $135.97M.
What does R&D mean?: Costs of research activities to discover new knowledge and development activities to translate research into new or improved products, services, processes, or technologies.